IRCT20161206031256N3 IRCT 2020-06-02 Mashhad University of Medical Sciences Using interferon to treat COVID-19 Evaluation and comparison of the effect of two interferon alpha and beta antiviral drugs on the prognosis of patients with COVID 19 2020-05-23 anticipated 76 Complete https://irct.ir/trial/48329 interventional Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Crossover, Purpose: Treatment, Randomization description: Simple Randomization using the envelope placement method, Blinding description: Eligible patient will be randomized in 4 groups, two groups will receive interferon (alpha or beta) and two group will receive placebo. the subjects, investigator, and the data analysts will remain blinded. 2-3 COVID-19. Intervention 1: Intervention group 1: patients who will receive standard care plus 4 consecutive doses of intramuscular injection of beta-interferon (each vial contains 30 micrograms of interferon equivalent to 6 million international units. Intervention 2: Intervention group 2: : patients who will receive standard care plus 2 doses of subcutaneous injection of Alpha-interferon (each vial contains 180 micrograms of interferon) with 7 day interval. Intervention 3: Control group 1: patients who will receive standard care plus beta-interferon placebo. Intervention 4: Control group 2: patients who will receive standard care plus alpha-interferon placebo. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information